Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2025-11-05 · generated 2026-08-03.
Latest call digest
Penumbra, Inc., Q3 2025 Earnings Call, Nov 05, 2025 · 2025-11-05T21:30:00
Q3 2025 (call held Nov 5, 2025). The prepared remarks were unusually strong: total revenue of $354.7 million (+17.8% reported), U.S. VTE up 34%, U.S. embolization and access up 29.2%, gross margin of 67.8%, and a raised full-year revenue guide of $1.375 billion to $1.380 billion with U.S. thrombectomy reiterated at 20% to 21%. Management leaned into two catalysts — a positive STORM-PE randomized readout (presented at TCT/VIVA and published in Circulation) and the newly split, ~50-person dedicated embolization sales force that drove 21.2% sequential Embo growth. On Thunderbolt, they said they had submitted responses to all outstanding FDA questions in October and are in a final clarification phase.
The Q&A told a more guarded story. Analysts pressed hardest on Thunderbolt's FDA timing, and management stayed deliberately prudent — level-setting the review as normal for a brand-new neuro product and declining to commit to a clearance date. A second recurring push was on conservatism: several analysts questioned why the raised guide implies a sequential slowdown into Q4, and management declined to give any 2026 framing. Beneath the strong venous and embolization numbers, management acknowledged the U.S. stroke market showed a slight decline in the quarter, which they framed as a cyclical 'wave' rather than a share loss.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Cecilia Furlong — Director of Business Development, Penumbra, Inc.; Adam Elsesser — Co-Founder, Chairman & CEO, Penumbra, Inc.; Shruthi Narayan — President, Penumbra, Inc.; Maggie Yuen — Chief Financial Officer, Penumbra, Inc. | 5 |
| Analysts | Travis Steed — Managing Director, BofA Securities, Research Division; Robert Marcus — Analyst, JPMorgan Chase & Co, Research Division; Larry Biegelsen — Senior Medical Device Equity Research Analyst, Wells Fargo Securities, LLC, Research Division; Joanne Wuensch — Managing Director, Citigroup Inc., Research Division; Vijay Kumar — Senior Managing Director of Equities, Evercore Inc.; Brandon Vazquez — Analyst, William Blair & Company L.L.C., Research Division; William Plovanic — Managing Director of Life Science Research, Canaccord Genuity Corp., Research Division; Michael Sarcone — Equity Analyst, Jefferies LLC, Research Division; Pito Chickering — Research Analyst, Deutsche Bank AG, Research Division; Ryan Zimmerman — MD & Medical Technology Analyst, BTIG, LLC, Research Division | 10 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Travis Steed | BofA Securities | Thunderbolt FDA process and launch timing | Asked whether Thunderbolt could be cleared by year-end; management level-set the review as normal for a brand-new neuro product and declined to commit to timing pending a clearance letter. |
| Robert Marcus | JPMorgan | U.S. thrombectomy deceleration and the stroke market | Asked if the year-long U.S. thrombectomy slowdown continues; management tied it to a soft stroke market offset by strong VTE, framing it as cyclical waves rather than a decline in their business. |
| Larry Biegelsen | Wells Fargo Securities | Embolization strength and implied Q4 deceleration | Questioned whether Q3 Embo strength was one-time and why the guide implies a Q4 slowdown; management said nothing was one-time and declined to give backdoor 2026 guidance. |
| William Plovanic | Canaccord Genuity | Guidance conservatism and FDA testing | Pushed on why the high end implies only ~2% sequential growth versus ~5% in prior years, and whether the FDA wants more data; management defended the conservative raise and stayed prudent on Thunderbolt. |
| Vijay Kumar | Evercore | STORM-PE practice change and SG&A step-up | Asked if STORM-PE is enough to change practice and about the sharp SG&A rise; management pointed to hospital protocol changes underway and said the embolization sales build-out is now complete. |
| Pito Chickering | Deutsche Bank | Market share versus market growth and new accounts | Asked to quantify new accounts and PER teams; management declined precise counts, saying a large share of growth was share gain and pointing to post-STORM conversion momentum. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| VTE-led CAVT thrombectomy growth | persisted | Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | U.S. VTE has led corporate growth every quarter, running near 40%+ from late 2024 through mid-2025 and 34% in Q3 2025; management repeatedly attributes it to Flash 2.0 share gains and calls the pattern non-linear. |
| Thunderbolt / THUNDER regulatory path | persisted | Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | Every call features a Thunderbolt update, moving from trial enrollment to FDA submission (Q1 2025) to active review (Q3 2025). Management has consistently refused to commit to timing and keeps Thunderbolt revenue out of guidance. |
| Conservative guidance philosophy | emerged | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | After cutting 2024 guidance, management adopted an explicit conservatism, repeatedly citing lessons learned about not getting ahead of itself. It has since raised the 2025 guide each quarter. |
| China / international headwind | persisted | Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | A multi-quarter China drag (as the model shifted from licensing to distribution) weighed on international results; by Q3 2025 management said the headwind is nearly minimal and other international regions returned to double-digit growth. |
| Gross margin path to 70% by end of 2026 | persisted | Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | A standing target reiterated every call, driven by CAVT product mix and manufacturing efficiency rather than price; gross margin reached 67.8% in Q3 2025. |
| STORM-PE randomized trial in PE | persisted | Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025 | Discussed as the key clinical catalyst, moving from ongoing enrollment to completion (Q2 2025) to a positive readout at TCT/VIVA (Q3 2025). Management frames it as potentially standard-of-care changing for PE. |
| Dedicated embolization sales force split | emerged | Q1 2025, Q2 2025, Q3 2025 | A new theme in 2025: management split off a ~50-person embolization team so the peripheral team can focus solely on CAVT thrombectomy. It drove 21.2% sequential Embo growth in Q3 2025 and the build-out is now complete. |
| Immersive Healthcare wind-down | dropped | Q2 2024, Q3 2024, Q4 2024, Q1 2025 | The 2024 decision to exit Immersive Healthcare was a major strategic topic and later a cost-savings driver, but it fell out of active discussion by mid-2025, surviving only as a small non-GAAP reconciliation item. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “we introduced guidance for total revenue in the range of $1.230 billion to $1.270 billion, representing year-over-year growth of 16% to 20% compared to $1,058.5 million in total revenue in 2023.” | Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024 · 2024-02-22T21:30:00 | Jason Mills | missed | This original 2024 guide (and the 27% to 30% U.S. thrombectomy target) was cut mid-2024; full-year 2024 revenue landed near $1.2 billion, below the original range. |
| “Our updated guidance range for 2024 includes total revenue of $1.180 billion to $1.200 billion which is a reduction of $60 million at the midpoint from our previous guidance range.” | Penumbra, Inc., Q2 2024 Earnings Call, Jul 30, 2024 · 2024-07-30T20:30:00 | Jason Mills | kept | The reset 2024 guide held: management reported full-year 2024 revenue of $1.2 billion and U.S. thrombectomy growth of 26.8%. |
| “our total revenue guidance for 2025 is a range of $1.340 billion to $1.360 billion, which represents year-over-year growth of 12% to 14% compared to 2024 GAAP total revenue.” | Penumbra, Inc., Q4 2024 Earnings Call, Feb 18, 2025 · 2025-02-18T21:30:00 | Jason Mills | pending | This initial 2025 guide was subsequently raised each quarter through the year, reaching $1.375 billion to $1.380 billion by Q3 2025. |
| “we are increasing our guidance for total revenue to a range of $1.355 billion to $1.370 billion, which represents 13% to 15% year-over-year growth.” | Penumbra, Inc., Q2 2025 Earnings Call, Jul 29, 2025 · 2025-07-29T20:30:00 | Jason Mills | pending | Raised again the following quarter to $1.375 billion to $1.380 billion; full-year 2025 outcome not yet known as of the latest call. |
| “we are raising our revenue guidance for the year to $1.375 billion to $1.380 billion. We reiterate 20% to 21% year-over-year growth for 2025 for U.S. thrombectomy.” | Penumbra, Inc., Q3 2025 Earnings Call, Nov 05, 2025 · 2025-11-05T21:30:00 | Adam Elsesser | pending | Most recent guide; full-year 2025 results not yet reported. Analysts noted the high end implies a sequential slowdown into Q4. |
| “remain well-positioned to deliver our long-term gross margin profile of 70% by the end of 2026.” | Penumbra, Inc., Q3 2025 Earnings Call, Nov 05, 2025 · 2025-11-05T21:30:00 | Maggie Yuen | pending | Standing multi-year target reiterated across calls; the end-of-2026 milestone is beyond the supplied call history. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| Thunderbolt FDA timing and clearance | 7 | BofA Securities, Canaccord Genuity, BTIG, Wells Fargo Securities | The most persistently pressed topic across the Q2 and Q3 2025 calls. Management repeatedly declined to give a clearance timeline, saying it does not control the FDA process and will stay prudent until it has a clearance letter — a conservative non-answer rather than an evasion of substance. |
| Guidance conservatism and implied deceleration | 6 | Canaccord Genuity, Wells Fargo Securities, BofA Securities, Truist Securities, Deutsche Bank | Analysts repeatedly asked why raised guides imply sequential deceleration despite strong beats; management defended the conservatism and declined to give forward 2026 framing. |
| STORM-PE clinical impact and adoption pace | 6 | BofA Securities, Evercore, William Blair, Jefferies, Deutsche Bank | Heavily probed on the Q3 2025 call — whether the data changes practice and how fast adoption follows. Management answered directly, pointing to hospital protocol updates and early conversions. |
| Stroke market softness / U.S. thrombectomy deceleration | 4 | JPMorgan, Truist Securities, William Blair | Analysts questioned the softening U.S. stroke market and decelerating U.S. thrombectomy; management acknowledged the soft stroke market but framed it as cyclical while continuing to take share. |
| Margins and operating leverage | 5 | JPMorgan, Evercore, Piper Sandler, BTIG | Recurring questions on the path to 70% gross margin and SG&A leverage after the sales-force build-out; management attributed expansion to CAVT mix and efficiency, not price, and said the investment phase is complete. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| The explicit birth of a conservative guidance stance after the 2024 cut — a deliberate shift away from the company's historically aspirational guiding. | “Going forward, our guidance will reflect a comfortable level of conservatism.” | 1886540871 | 2 |
| A year later, management still invokes the 2024 miss as a self-check on optimism, signaling the conservatism is durable rather than a one-quarter posture. | “we still have fresh memories of having our enthusiasm get the better of us, and we're going to try not to do that.” | 1951480879 | 25 |
| New caution vocabulary about the core stroke market surfaced in Q3 2025, an acknowledgment absent from the confident stroke commentary of prior quarters. | “Recent market trends in the macro U.S. stroke market showed a slight decline in the third quarter.” | 1964400815 | 2 |
| Confidence on the PE clinical thesis hardened once STORM-PE read out — language moved from conditional ('if positive') to definitive claims of superiority. | “STORM-PE proved CAVT superior to the current standard of care across the primary as well as multiple secondary endpoints” | 1964400815 | 3 |
The call history shows a company that reset its own credibility after over-promising in early 2024, then strung together in-line-to-raised quarters under a deliberately conservative guide. For the current debate, two threads dominate: Thunderbolt's uncertain FDA timing, which management keeps out of guidance, and whether the positive STORM-PE readout converts into faster PE-market growth — a potential offset to a stroke market that management has just conceded is softening.